Circulating biomarkers for cancer
OwnerTraci Pawlowski, Kimberly Yeatts +1inventors
InventorsTraci Pawlowski, Kimberly Yeatts, Ray Akhavan
Life of this patent
Estimating the term…
Abstract
Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes.
Claims47
A method comprising:
- (a) determining a presence or level of one or more biomarker associated with a microvesicle population in a biological sample from a subject, wherein the at least one biomarker is selected from the group consisting of A2ML1, BAX, C10orf47, C10orf162, CSDA, EIFC3, ETFB, GABARAPL2, GUK1, GZMH, HIST1H3B, HLA-A, HSP90AA1, NRGN, PRDX5, PTMA, RABAC1, RABAGAP1L, RPL22, SAP18, SEPW1, SOX1, and a combination thereof;
- and
- (b) identifying a microvesicle biosignature comprising the presence or level of the at least one biomarker.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.